Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PCSA 
Processa Pharmaceuticals Inc (PCSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: PCSA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -61.1% | Avg. Invested days 19 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.09M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 4493837 | Beta 1.37 | 52 Weeks Range 0.15 - 3.10 | Updated Date 06/13/2025 |
52 Weeks Range 0.15 - 3.10 | Updated Date 06/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -102.42% | Return on Equity (TTM) -192.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 224693 | Price to Sales(TTM) - |
Enterprise Value 224693 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 11884400 | Shares Floating 11244265 |
Shares Outstanding 11884400 | Shares Floating 11244265 | ||
Percent Insiders 5.13 | Percent Institutions 1.44 |
Analyst Ratings
Rating 3 | Target Price 6 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Processa Pharmaceuticals Inc
Company Overview
History and Background
Processa Pharmaceuticals Inc. was founded in 2007. It focuses on developing therapies to improve the survival and quality of life for cancer patients. The company has transitioned from initial research to clinical-stage development of multiple product candidates.
Core Business Areas
- Drug Development: Developing novel therapies for cancer patients with unmet medical needs, focusing on next generation chemotherapy plus/minus immunotherapy combinations to treat a variety of tumors in patients who have not tolerated or are resistant to current therapies.
Leadership and Structure
The leadership team includes experienced pharmaceutical executives. The company operates with a small, focused team and leverages external partnerships for various aspects of drug development.
Top Products and Market Share
Key Offerings
- Next Generation Chemotherapy plus/minus Immunotherapy combinations: Processa is developing various new treatments for multiple types of tumors. PCS350065 is a novel, next generation capecitabine, a standard chemotherapy used to treat breast and colorectal cancers and also gastric and pancreatic cancers. PCS400 (Nexavar/sorafenib) is being developed as a combination therapy to address drug resistance in various cancers. PCS3110 (Ondansetron IV) is intended to be used to manage moderate to severe nausea and vomiting in cancer patients receiving multiple-day chemotherapy. There is no current market share data available as these products are under development and not yet approved for commercial sale. Competitors depend on the individual cancer types. In the breast cancer and colorectal market, there are a number of established pharmaceutical companies such as Roche, Pfizer, Novartis and Merck
Market Dynamics
Industry Overview
The pharmaceutical industry, especially oncology, is characterized by intense competition, high regulatory hurdles, and significant investment in research and development. The market is driven by an aging population, increasing cancer incidence, and advancements in drug development technologies.
Positioning
Processa Pharmaceuticals is positioned as a clinical-stage company focused on developing innovative therapies to address unmet needs in cancer treatment. Their competitive advantage lies in their novel approach to improving the efficacy and reducing the toxicity of existing chemotherapies.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Processa is targeting specific niches within this market, such as patients with resistance to standard chemotherapy treatments, thus the overall TAM is dependent on the success of the trials. Given its early stage, its current positioning is focused on clinical development.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced management team
- Focus on unmet medical needs in oncology
- Pipeline of clinical-stage product candidates
Weaknesses
- Limited financial resources
- Dependence on external partnerships
- High risk of clinical trial failures
- No currently approved products
Opportunities
- Positive clinical trial results
- Strategic collaborations with larger pharmaceutical companies
- FDA approval and commercialization of product candidates
- Expansion of pipeline through in-licensing or acquisition
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Patent challenges
- Financing risks
Competitors and Market Share
Key Competitors
- ROCHE (RHHBY)
- PFIZER (PFE)
- NOVARTIS (NVS)
- MERCK (MRK)
Competitive Landscape
Processa Pharmaceuticals faces intense competition from larger pharmaceutical companies with significantly more resources. Its advantages are its novel approach and focus on specific unmet needs. Its disadvantages are limited financial resources and lack of approved products.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by advancement of pipeline candidates through clinical trials. Key milestones include initiating, completing, and reporting results from clinical studies.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely due to the inherent uncertainty of drug development.
Recent Initiatives: Recent strategic initiatives include advancing product candidates through clinical trials (e.g., PCS350065, PCS400, PCS3110) and securing financing for operations.
Summary
Processa Pharmaceuticals is a clinical-stage biopharmaceutical company with a novel approach to treating cancer. The company is working towards developing innovative therapies to address unmet needs in cancer treatment. Its small size and dependence on financing are significant risks. Positive clinical trial results are critical for its success, otherwise it will have a very hard time surviving as a company. It is looking to address an unmet need in the oncology sector through novel cancer drugs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is approximate and based on overall oncology market, not specific product niches.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Processa Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Hanover, MD, United States | ||
IPO Launch date 2017-10-10 | CEO & Director Mr. George K. Ng Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | |
Full time employees 10 | |||
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.